FrancophonIA/ELRC3.0 huggingface dataset:
English: Ensure that the entire contents of the vial are drawn into the syringe.
Maltese: Kun ċert li t-trab ikun inħall kollu.
English: VWF is not present in rFVIII, but there is significant heterogeneity within the rFVIII class for instance due to the different manufacturing processes used, with a wide range of products from different manufacturers produced over the past 20 years.
Maltese: VWF mhuwiex preżenti f'rFVIII, iżda hemm eteroġeneità sinifikanti fil-klassi rFVIII, pereżempju, minħabba lproċessi differenti ta' manifattura li jintużaw, b'medda vasta ta' prodotti minn manifatturi differenti prodotti matul l-aħħar 20 sena.
English: The available data supports a frequency of FVIII inhibitor development within the frequency of ‘very common' and ‘uncommon', for PUPs and PTPs respectively, therefore the PRAC recommends that the SmPCs should be aligned with these frequencies unless justified by product specific data.
Maltese: Id-dejta disponibbli tappoġġja frekwenza taliżvilupp tal-inibitur FVIII fil-frekwenza ta' “komuni ħafna” u “mhux komuni” għall-PUPs u għall-PTPs rispettivament, għalhekk il-PRAC jirrakkomanda li l-SmPCs għandhom jiġu allinjati ma' dawn il-frekwenzi sakemm ma jiġix iġġustifikat minn dejta speċifika għallprodott.
English: After reconstitution, the chemical and physical in-use stability has been demonstrated for 3 hours in in vitro studies.
Maltese: Wara r-rikostituzzjoni, l-istabbilità kimika u fiżika waqt l-użu ntweriet għal 3 sigħat fi studji in vitro.
English: If you have any questions about this medicine and compatible separate filters, contact your doctor.
Maltese: Jekk għandek xi mistoqsijiet dwar din il-mediċina u filtri separati kompatibbli, ikkuntattja lit-tabib tiegħek.
English: The most serious side effects are hypersensitivity reactions or anaphylactic shock (rare side effect).
Maltese: L-iktar effetti sekondarji serji huma reazzjonijiet ta' sensittività eċċessiva jew xokk anafilattiku (effett sekondarju rari).
English: You may be at risk of CVAD-related complications including local infections, bacteria in the blood (bacteremia) and the formation of a blood clot in the blood vessel (thrombosis) where the catheter is inserted.
Maltese: Tista' tkun f'riskju ta' komplikazzjonijiet relatati ma' CVAD inkluż infezzjonijiet lokali, batterja fid-demm (batterimja) u l-formazzjoni ta' embolu tad-demm filkanal tad-demm (trombożi) fejn jiddaħħal il-kateter.
English: KOGENATE Bayer is not likely to affect the fertility in male or female patients, as the active substance is naturally occurring in the body.
Maltese: KOGENATE Bayer mhux probabbli li jaffettwa l-fertilità f'pazjenti rġiel jew nisa, peress li s-sustanza attiva sseħħ b'mod naturali fil-ġisem.
English: Treatment of congenital haemophilia is currently based on prophylactic or on-demand replacement therapy with coagulation factor VIII (FVIII).
Maltese: Il-kura ta' emofilja konġenitali bħalissa hija bbażata fuq terapija sostituttiva profilattika jew indipendenti bil-fattur ta' koagulazzjoni VIII (FVIII).
English: This is similar to that of plasmaderived factor VIII which has a mean terminal half-life of approx. 13 hours.
Maltese: Dan huwa simili għal dak ta' fattur VIII li ġej mill-plażma li għandu half-life terminali medja ta' madwar 13-il siegħa.
English: (pre- and postoperative)
Maltese: (qabel u wara lkirurġija)
English: The potency (IU) is determined using the one-stage clotting assay against the FDA Mega standard which was calibrated against WHO standard in International Units (IU).
Maltese: Il-qawwa (IU) hija determinata permezz ta' assaġġ tal-emboliżmu ta' stadju wieħed li jitqabbel malMega standard tal-FDA li ġie kkalibrat ma' standard tal-WHO f'Unitajiet Internazzjonali (IUInternational Units).
English: KOGENATE Bayer 250 IU powder and solvent for solution for injection KOGENATE Bayer 500 IU powder and solvent for solution for injection KOGENATE Bayer 1000 IU powder and solvent for solution for injection KOGENATE Bayer 2000 IU powder and solvent for solution for injection KOGENATE Bayer 3000 IU powder and solvent for solution for injection
Maltese: IU trab u solvent għal soluzzjoni għall-injezzjoni KOGENATE Bayer 3000 IU trab u solvent għal soluzzjoni għall-injezzjoni
English: There was also evidence for an increased risk with Refacto AF (another 3rd generation rFVIII) vs Advate, but only for all inhibitor development.
Maltese: Kien hemm ukoll evidenza għal riskju miżjud b'Refacto AF (rFVIII tat-3et ġenerazzjoni ieħor) vs Advate, iżda għall-iżvilupp talinibituri kollha biss.
English: Inject the solution into a vein over 2 to 5 minutes, keeping an eye on the position of the needle.
Maltese: Injetta s-soluzzjoni ġol-vina fuq medda ta' 2 sa 5 minuti, waqt li żżomm għajnejk fuq ilpożizzjoni tal-labra.
English: This will usually be in the range of 20 to 40 IU of octocog alfa per kg of body weight, given every 2 to 3 days.
Maltese: Din ġenerlament tkun fil-firxa ta' 20 sa 40 IU ta' octocog alfa għal kull kg ta' piż tal-ġisem, mogħtija kull jumejn sa 3 ijiem.
English: • one pre-filled syringe with 2.5 mL (for 250 IU, 500 IU and 1000 IU) or 5 mL (for 2000 IU and
Maltese: IU) jew 5 mL (għal 2000
English: Even doses several fold higher than the recommended clinical dose (related to body weight) failed to demonstrate any acute or subacute toxic effects for KOGENATE Bayer in laboratory animals (mouse, rat, rabbit, and dog).
Maltese: Anke dożi li huma diversi drabi ogħla mid-doża klinika rakkomandata (meta mqabbel mal-piż talġisem) naqsu milli juru effetti ta' tossiċità akuta jew subakuta ta' KOGENATE Bayer fuq annimali tal-laboratorju (ġurdien, far, fenek, u kelb).
English: KOGENATE Bayer 3000 IU contains (3000 IU / 5 mL) = 600 IU octocog alfa per mL after reconstitution.
Maltese: KOGENATE Bayer 3000 IU fih (3000
English: b) By continuous infusion Raise factor VIII activity presurgery with an initial bolus infusion and immediately follow with continuous infusion (in IU/kg/h) adjusting according to patient's daily clearance and desired factor VIII levels for at least 7 days.
Maltese: b) Permezz ta' infużjoni kontinwa Għolli l-attività tal-fattur VIII qabel l-intervent kirurġiku permezz ta' infużjoni bolus fil-bidu u segwi minnufih b'infużjoni kontinwa (f'IU/kg/siegħa) u aġġusta skont ittneħħija ta' kuljum tal-pazjent u llivelli ta' fattur VIII mixtieqa almenu għal 7 ijiem
English: PHARMACEUTICAL FORM Powder and solvent for solution for injection (vial adapter).
Maltese: Trab u solvent għal soluzzjoni għall-injezzjoni (adattatur tal-kunjett).
English: • one vial plus Bio-Set system, containing powder (10 mL clear glass type 1 vial with latex-free grey halogenobutyl rubber blend stopper plus transfer system with protective cap [Bio-Set])
Maltese: flimkien ma' sistema li titrasferixxi b'għatu protettiv [Bio-Set]). - siringa waħda mimlija għal-lest b' 2.5 mL (għal 250
English: The MAHs provided an analysis of low and high titre inhibitor development in PUPs with severe haemophilia A (FVIII < 1%) from all clinical trials and observational studies conducted with their products, along with critical discussion on the limitations of these studies.
Maltese: L-MAHS ipprovdew analiżi ta' żvilupp tal-inibituri ta' titre baxx u għoli f'PUPs b'emofilja A severa (FVIII < 1%) mill-provi kliniċi u l-istudji ta' osservazzjoni kollha li saru bil-prodotti tagħhom, flimkien ma' diskussjoni kritika dwar il-limitazzjonijiet ta' dawn l-istudji.
English: The SIPPET study was not designed to evaluate the risk of inhibitor development for individual products, and included a limited number of FVIII products.
Maltese: L-istudju SIPPET ma tfassalx biex jevalwa r-riskju ta' żvilupp tal-inibituri għal prodotti indivdwali, u inkluda numru limitat ta' prodotti FVIII.
English: Class
Maltese: Trab
English: PRAC also considered grounds submitted by LFB Biomedicaments as basis for their request for reexamination of the PRAC recommendation and the views of two experts meetings held on 22 February and 3 August 2017.
Maltese: Il-PRAC ikkunsidra wkoll ir-raġunijiet ippreżentati minn LFB Biomedicaments bħala bażi għat-talba tagħhom għal eżaminazzjoni mill-ġdid tarrakkomandazzjoni tal-PRAC u l-fehmiet ta' żewġ laqgħat ta' esperti li saru fit-22 ta' Frar u fit-3 ta' Awwissu 2017.
English: 2 dry swabs
Maltese: 2 imsielaħ xotti
English: Consequently, patients should be evaluated and monitored for cardiac risk factors.
Maltese: B'konsegwenza ta' dan, il-pazjenti għandhom jiġu evalwati u mmonitorjati għal fatturi ta' riskju kardijaċi.
English: One International Unit (IU) of factor VIII activity is equivalent to that quantity of factor VIII in one mL of normal human plasma.
Maltese: Unità Internazzjonali waħda (IU - International Unit) ta' attività tal-fattur VIII, hija ekwivalenti għallammont ta' fattur VIII li hemm ġo mL wieħed ta' plażma normali tal-bniedem.
English: • The PRAC noted that the efficacy and safety of Factor VIII products as indicated in the treatment and prophylaxis of bleeding in patients with haemophilia A have been established.Based on the available data, the PRAC considered that SmPC updates for the FVIII products are warranted: section 4.4 should be amended to include a warning on the clinical importance of monitoring patients for FVIII inhibitor development.
Maltese: B'mod ġenerali l-pazjenti kollha ttrattati bi prodotti ta' fattur VIII tal-koagulazzjoni, għandhom jiġu ssorveljati bir-reqqa għall-iżvilupp ta' inibituri permezz ta' osservazzjonijiet kliniċi u testijiet tallaboratorju xierqa.
English: For long term prophylaxis against bleeding in patients with severe haemophilia A, the usual doses are 20 to 40 IU of KOGENATE Bayer per kg body weight at intervals of 2 to 3 days.
Maltese: Għall-profilassi fit-tul kontra fsada f'pazjenti li għandhom emofilija A severa, id-dożi tas-soltu huma ta' 20 sa 40 IU ta' KOGENATE Bayer għal kull kg ta' piż tal-ġisem f'intervalli ta' jumejn sa 3 ijiem.
English: Specifically, the findings from the SIPPET study, as well as those from the individual clinical trials and observational studies included in the MAH responses, are not sufficient to confirm any consistent statistically and clinically meaningful differences in inhibitor risk between the rFVIII and pdFVIII product classes.
Maltese: Speċifikament, is-sejbiet mill-istudju SIPPET, kif ukoll dawkmill-provi kliniċi individwali u mill-istudji ta' osservazzjoni inklużi fit-tweġibiet tal-MAH, mhumiex biżżejjed biex jikkonfermaw xi differenza statistikament konsistenti u klinikament sinifikanti fir-riskju ta' inibituri bejn klassijiet tal-prodotti rFVIII u pdFVIII.
English: This trial, known as the SIPPET study (“Survey of Inhibitors in PlasmaProduct Exposed Toddlers”) was conducted to evaluate the relative risk of inhibitors in patients treated with pdFVIII compared to rFVIII.
Maltese: L-istudji kienu l-aktar ta' fergħa waħda u ma pprovdewx dejta biex iwettqu analiżi komparattiva (jew bejn pdFVIII u rFVIII bħala tqabbil bejn il-klassi, jew filklassi rFVIII).
English: initiation pack: 14 tablets + 14 tablets + 14 tablets +14 tablets
Maltese: Daqs tal-pakkett folja (PVC/PVDC/alu) pakkett tal-bidu: 14-il pillola + 14il pillola + 14il pillola +14il pillola
English: The full EPAR for Picato can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This summary was last updated in 11-2012.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar fi 11-2012.
English: EPAR summary for the public ingenol mebutate
Maltese: Sommarju tal-EPAR għall-pubbliku ingenol mebutate
English: Picato is a medicine containing the active substance ingenol mebutate.
Maltese: Picato huwa mediċina li fiha s-sustanza attiva ingenol mebutate.
English: It is available as a gel in two strengths (150 micrograms/g and 500 micrograms/g).
Maltese: Jiġi bħala ġell f'żewġ qawwiet (150 mikrogramma/g u 500 mikrogramma/g).
English: The European Commission granted a marketing authorisation valid throughout the European Union for Picato on 15 November 2012.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq fl-Unjoni Ewropea kollha għal Picato fil-15 ta' Novembru 2012.
English: This is a summary of the European public assessment report (EPAR) for Picato.
Maltese: Dan huwa sommarju tar-Rapport Pubbliku Ewropew ta' Valutazzjoni (EPAR) għal Picato.
English: It is thought that the active substance in Picato, ingenol mebutate, works in two different ways.
Maltese: Huwa maħsub li s-sustanza attiva f'Picato, ingenol mebutate, taħdem f'żewġ modi differenti.
English: The most frequently reported side effects are skin reactions at the application site of Picato, including erythema (reddening of the skin), flaking or scaling, crusting, swelling, vesiculation or pustulation (blisters), and erosion or ulceration (wearing away of outer skin layer or open sore of the skin).
Maltese: L-effetti sekondarji rrapportati l-aktar frekwenti huma reazzjonijiet fil-ġilda fil-post fejn jiġi applikat Picato, inkluż eritema (ħmura fil-ġilda), frak jew qxur, skorċa, nefħa, bżieżaq jew infafet, u tgħawwir jew ulċeri (is-saff ta' fuq tal-ġilda jittiekel jew feriti miftuħa fil-ġilda).
English: What is Picato?
Maltese: X'inhu Picato?
English: Picato (500 microgram/g) has been studied in two studies involving 458 adults with actinic keratosis affecting the trunk and extremities, where it was applied once a day for two consecutive days.
Maltese: Picato (500 mikrogramma/g) ġie studjat f'żewġ studji li kienu jinvolvu 458 adult b'keratosi aktinika fissider u fl-estremitajiet, fejn ġie applikat darba kuljum għal jumejn konsekuttivi.
English: How has Picato been studied?
Maltese: Kif ġie studjat Picato?
English: For actinic keratosis of the trunk and extremities, the first study showed that the skin cleared completely in 28% (35 out of 126) of patients treated with Picato, compared with 5% (6 out of 129) of patients treated with placebo.
Maltese: Għall-keratosi aktinika tas-sider u l-estremitajiet, l-ewwel studju wera li l-ġilda kienet iċċarat għal kollox fi 28% (35 minn 126) tal-pazjenti kkurati b'Picato, meta mqabbel ma' 5% (6 minn 129) talpazjenti kkurati bil-plaċebo.
English: In the second study, the skin cleared in 42% (42 out of 100) of patients treated with Picato, compared with 5% (5 out of 103) of patients treated with placebo.
Maltese: Fit-tieni studju, il-ġilda ċċarat fi 42% (42 minn 100) tal-pazjenti kkurati b'Picato, meta mqabbel ma' 5% (5 minn 103) tal-pazjenti kkurati bil-plaċebo.
English: The content of one tube covers a treatment area of 25 cm2.
Maltese: Il-kontenut ta' stoċċ wieħed ikopri żona ta' trattament ta' 25 cm2.
English: Why has Picato been approved?
Maltese: Għaliex ġie approvat Picato?
English: In all four studies, Picato was compared with vehicle (a gel without active substance).
Maltese: Fl-erba' studji, Picato tqabbel ma' vettura (ġell mingħajr sustanza attiva).
English: Picato was shown to be effective in clearing actinic keratosis from the skin.
Maltese: Picato intwera li kien effettiv fl-eliminazzjoni tal-keratosi aktinika minn fuq il-ġilda.
English: Picato (150 microgram/g) has been studied in two main studies involving 547 adults with actinic keratosis affecting the face and scalp, where it was applied once a day for three consecutive days.
Maltese: Picato (150 mikrogramma/g) ġie studjat f'żewġ studji ewlenin li kienu jinvolvu 547 adult b'keratosi aktinika fil-wiċċ u fil-qorriegħa, fejn ġie applikat darba kuljum għal tliet ijiem konsekuttivi.
English: The CHMP noted that treatment with Picato has a beneficial effect.
Maltese: Is-CHMP innota li l-kura b'Picato għandha effett benefiku.
English: What is the risk associated with Picato?
Maltese: X'inhu r-riskju assoċjat ma' Picato?
English: The effects of Picato were first tested in experimental models before being studied in humans.
Maltese: L-effetti ta' Picato ġew ittestjati għall-ewwel darba f'mudelli sperimentali qabel ma ġew studjati filbniedem.
English: In the second study the skin completely cleared in 37% (50 out of 135) of patients treated with Picato, compared with 2% (3 out of 134) of patients treated with placebo.
Maltese: Fit-tieni studju l-ġilda kienet iċċarat għal kollox f'37% (50 minn 135) talpazjenti kkurati b'Picato, meta mqabbel ma' 2% (3 minn 134) tal-pazjenti kkurati bil-plaċebo.
English: For actinic keratosis affecting the face and scalp, the first study showed that the skin completely cleared in 47% (67 out of 142) of patients treated with Picato, compared with 5% (7 out of 136) of patients treated with placebo.
Maltese: Għall-keratosi aktinika li taffettwa l-wiċċ u l-qorriegħa, l-ewwel studju wera li l-ġilda kienet iċċarat għal kollox f'47% (67 minn 142) tal-pazjenti kkurati b'Picato, meta mqabbel ma' 5% (7 minn 136) talpazjenti kkurati bil-plaċebo.
English: Picato is used to treat adults with actinic keratosis.
Maltese: Picato jintuża għall-kura tal-adulti li jbatu minn keratosi aktinika.
English: Picato gel is applied to the affected skin areas.
Maltese: Il-ġell Picato jiġi applikat fuq iż-żoni tal-ġilda affettwata.
English: In addition, the CHMP considered the fact that Picato can be self-applied and that treatment is of short duration as an advantage.
Maltese: Barra minn hekk, is-CHMP ikkunsidra li l-fatt li Picato jista' jiġi applikat mill-pazjent stess u li l-kura ddum biss ftit jiem huwa vantaġġ.
English: Once applied and absorbed by the skin cells, ingenol mebutate has a direct toxic effect on the cell as well as promoting an inflammatory response.
Maltese: Ladarba jiġi applikat u assorbit miċ-ċelloli tal-ġilda, ingenol mebutate ikollu effett tossiku dirett fuq iċ-ċellola kif ukoll joħloq reazzjoni infjammatorja.
English: When the affected areas are the face, scalp and upper part of the neck, Picato (150 micrograms/g) should be applied once a day for three consecutive days.
Maltese: Meta ż-żoni affettwati jkunu l-wiċċ, ilqorriegħa u l-parti ta' fuq tal-għonq, Picato (150 mikrogramma/g) għandu jiġi applikat darba kuljum għal tliet ijiem konsekuttivi.
English: When the affected areas are the trunk, extremities and lower part of the neck, the higher strength Picato (500 micrograms/g) should be applied once a day for two consecutive days.
Maltese: Meta ż-żoni affettwati jkunu s-sider, l-estremitajiet u l-parti t'isfel talgħonq, Picato tal-ogħla qawwa (500 mikrogramma/g) għandu jiġi applikat darba kuljum għal jumejn konsekuttivi.
English: Other information about Picato
Maltese: Kif jintuża Picato?
English: Thyme
Maltese: Timu
English: Thyme EMA/307113/2016
Maltese: EMA/307113/2016
English: Thymus vulgaris L. and Thymus zygis L., herba
Maltese: Thymus vulgaris L. u Thymus zygis L., herba
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom20 September 2016 EMA/307113/2016
Maltese: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
English: What is thyme?
Maltese: X'inhu timu?
English: A clinical study involving 60 adults with productive cough treated either with a thyme preparation or bromhexine, an established treatment for productive coughs.
Maltese: Studju kliniku li involva 60 adult b'sogħla produttiva kkurati jew bi preparazzjoni tat-timu jew bi bromhexine, kura stabbilita għal sogħla produttiva.
English: Further information on the HMPC assessment of thyme medicines, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Maltese: Aktar informazzjoni dwar il-valutazzjoni tal-HMPC tal-mediċini li fihom it-timu, inklużi d-dettalji talkonklużjonijiet tal-Kumitat, tinsab taħt it-tab ‘Id-dokumenti kollha' (‘All Documents') fil-websajt talAġenzija: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: Thyme is the common name for the leaves and flowers of the plants Thymus vulgaris L. or Thymus zygis L.
Maltese: Timu huwa l-isem komuni għall-weraq u l-fjuri tal-pjanta Thymus vulgaris L. jew Thymus zygis L.
English: Other information about thyme medicines
Maltese: Aktar informazzjoni dwar il-mediċini li fihom it-timu
English: What are the risks associated with thyme medicines?
Maltese: X'inhuma r-riskji assoċjati mal-mediċini li fihom it-timu?
English: Although no significant difference was observed between thyme and bromhexine in treating the cough, there were shortcomings in the study such as the small number of patients and lack of details of the thyme preparation, so firm conclusions could not be drawn.
Maltese: Għalkemm ma ġiet osservata l-ebda differenza sinifikanti bejn it-timu u bromhexina fil-kura tas-sogħla, kien hemm nuqqasijiet fl-istudju bħan-numru żgħir ta' pazjenti u n-nuqqas ta' dettalji tal-preparazzjoni tat-timu, għalhekk ma setgħet tinstilet l-ebda konklużjoni soda.
English: How are thyme medicines approved in the EU?
Maltese: Kif jiġu approvati fl-UE l-mediċini li fihom it-timu?
English: Thyme medicines must not be used in patients who are allergic to thyme or to other plants of the Lamiaceae (Labiatae) family.
Maltese: Il-mediċini li fihom il-timu m'għandhomx jintużaw f'pazjenti li huma allerġiċi għat-timu jew pjanti oħrajn tal-familja Lamiaceae (Labiatae).
English: Extracts are obtained by putting the plant material in a solvent (such as ethanol) to dissolve compounds and form a liquid extract.
Maltese: L-estrazzjonijiet jinkisbu billi l-materjal tal-pjanta jitpoġġa f'solvent (bħall-etanol), biex jinħallu l-komponenti u jifforma estratt likwidu.
English: Further information on the risks associated with these thyme medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Maltese: Aktar informazzjoni dwar ir-riskji assoċjati ma' dawn il-mediċini li fihom it-timu, inklużi lprekawzjonijiet xierqa għall-użu sigur tagħhom, tinsab fil-monografija taħt it-tab ‘Id-dokumenti kollha' (‘All Documents') fil-websajt tal-Aġenzija:
English: Most thyme preparations should only be used in adults and adolescents over the age of 12 years, but a few can also be used in children above 4 years.
Maltese: Ħafna mill-preparazzjonijiet tat-timu għandhom jintużaw biss fl-adulti u fl-adoloxxenti li għandhom 'il fuq minn 12-il sena, iżda ftit minnhom jistgħu jintużaw ukoll fi tfal li għandhom aktar minn 4 snin.
English: Any applications for the licensing of medicines containing thyme have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC.
Maltese: Kwalunkwe applikazzjoni għal-liċenzjar ta' mediċini li fihom it-timu għandha titressaq lill-awtoritajiet nazzjonali responsabbli għall-prodotti mediċinali, li ser jivvalutaw l-applikazzjoni għall-mediċina talħxejjex u jqisu l-konklużjonijiet xjentifiċi tal-HMPC.
English: The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing thyme.
Maltese: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: In its assessment, the HMPC also considered clinical studies in both adults and children.
Maltese: Fil-valutazzjoni tiegħu, l-HMPC ikkunsidra wkoll studji kliniċi kemm fl-adulti kif ukoll fit-tfal.
English: What evidence supports the use of thyme medicines?
Maltese: X'evidenza tappoġġa l-użu tal-mediċini li fihom it-timu?
English: 2.5% glucose in Ringer solution.
Maltese: 2.5% glucose fi-soluzzjoni Ringer.
English: See section 6.2 for incompatibilities.
Maltese: Ara sezzjoni 6.2 għal inkompatibbilitajiet
English: Combination solutions for parenteral nutrition (amino acids, glucose, electrolytes).
Maltese: Kombinazzjoni ta' soluzzjonijiet għall-nutrizzjoni parenterali (amino acids, glucose, electrolytes).
English: Clear greenish-yellow isotonic solution with pH of 4.3 to 5.3 and osmolarity of 282 - 322 mOsm/litre.
Maltese: Soluzzjoni isotonika ċara ta' kulur ħadrani fl-isfar b'pH ta' 4.3 sa 5.3 u osmolarità ta' 282 - 322 mOsm/litru.
English: EUCAST clinical MIC breakpoints for levofloxacin (version 2.0, 2012-01-01):
Maltese: Breakpoints kliniċi ta' MIC tal- EUCAST għall-levofloxacin (verżjoni 2.0, 2012-01-01):
English: Tachycardia, Palpitation
Maltese: Takikardja, Palpitazzjoni